Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,131,518
+$421,384 QoQ
Shares Held
7,220
+55.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#583
of 1,603 holders
Holding Since
Sep 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026SYON CAPITAL LLC holds $48,543,750 across 15 Drug Manufacturers - General names. NVS ranks #9 (2.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
13,135 | $15,754,514 | |
| 2 | JNJ |
Johnson & Johnson
|
32,155 | $8,166,405 | |
| 3 | ABBV |
AbbVie Inc.
|
27,228 | $6,851,653 | |
| 4 | MRK |
Merck & Co., Inc.
|
29,362 | $3,773,017 | |
| 5 | AMGN |
Amgen Inc
|
8,459 | $3,063,173 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
20,463 | $2,585,295 | |
| 7 | AZN |
Astrazeneca PLC
|
12,068 | $2,288,334 | |
| 8 | GSK |
GSK plc
|
29,588 | $1,551,002 |
All Filings in NVS
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,131,518 | 7,220 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $710,134 | 4,649 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $638,475 | 4,631 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $557,331 | 4,346 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $231,492 | 1,913 | Shares | Sole | 2025-08-14 | |
| 2024-09-30 | $6,474,935 | 56,294 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $6,213,431 | 58,364 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $5,672,343 | 58,641 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $5,618,879 | 55,649 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | $6,568,136 | 64,482 | Shares | Sole | 2023-11-03 | |
| No filing history on record for this holder in this stock. | ||||||